# CERVAVAC (quadrivalent HPV vaccine, India)

Source: https://onco.cc/drugs/cervavac/  
OnCo record `cervavac` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

India's first home-made HPV vaccine, protecting against the two virus types that cause most cervical cancers and the two that cause genital warts, at a price meant for a national programme.

## Summary

CERVAVAC is a quadrivalent HPV vaccine (types 6, 11, 16 and 18) developed by the Serum Institute of India with Department of Biotechnology support and produced in Hansenula polymorpha yeast. It is indicated for girls and women aged 9 to 26 against cervical, vulvar, vaginal and anal cancers and genital warts, and for boys and men aged 9 to 26 against anal cancer and genital warts; the schedule is two doses at 0 and 6 months for ages 9 to 14 and three doses (0, 2 and 6 months) for ages 15 to 26. It received Indian market authorisation in 2022 and was introduced in 2023, and published comparisons report immunogenicity non-inferior to established vaccines.

Its importance is supply and price: India records about 127,500 cervical cancer cases and 79,900 deaths a year (GLOBOCAN 2022), and vaccination depended on two imported products. A domestic vaccine, together with the IARC India evidence that a single dose protects as well as two or three, is what makes a national programme for girls aged 9 to 14 affordable; its proposed inclusion in the Universal Immunisation Programme is described in the 2026 literature as a milestone still being rolled out.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Also known as: qHPV vaccine (Serum Institute); Cervavac
- Brand: CERVAVAC
- Modality: Prophylactic vaccine (virus-like particles)
- Mechanism: Recombinant L1 capsid proteins of HPV 6, 11, 16 and 18 self-assemble into virus-like particles that induce neutralising antibodies preventing persistent infection.
- Approvals: IN 2022: Prevention of HPV 6/11/16/18-related cancers and genital warts, ages 9-26
- Dosing: Intramuscular; Ages 9-14: two doses at 0 and 6 months; ages 15-26: three doses at 0, 2 and 6 months

## Sources

- Serum Institute of India: CERVAVAC: https://www.seruminstitute.com/product_ind_cervavac.php
- Cervical cancer elimination in India (Cancer 2026): https://doi.org/10.1002/cncr.70292
- New HPV vaccines on the market (Vaccines 2026): https://doi.org/10.3390/vaccines14020140

## Connected records

- drugs: [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/)
- ideas: [Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries](https://onco.cc/ideas/idea-single-dose-hpv-self-sampling-elimination/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- technologies: [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- companies: [Serum Institute of India](https://onco.cc/companies/serum-institute-of-india/)
- institutions: [Department of Biotechnology, Government of India](https://onco.cc/institutions/dbt-india/), [International Agency for Research on Cancer (IARC / WHO)](https://onco.cc/institutions/iarc/)
- trials: [IARC India HPV vaccine dose study (one, two or three doses)](https://onco.cc/trials/iarc-india-hpv-dose-study/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target](https://onco.cc/key-papers/paper-tamrakar-cancer/), [New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review](https://onco.cc/key-papers/paper-akgor-vaccines-basel/), [Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India](https://onco.cc/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/), [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/cervavac.json